Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
Last trade$30.16
Day change-$2.16 (-6.68%)
Day range$29.32 – $32.42
Volume163,956
Market cap$616M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$616.07M
Price / earnings
—
Price / book
-1.84×
Price / sales
58.52×
EV / sales
48.99×
EV / EBITDA
-10.13×
Profitability
Earnings per share
-$21.42
Return on assets
-374.51%
Return on equity
121.67%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
7.56×
Quick ratio
7.56×
Cash ratio
7.37×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$30.78M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SRZN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$5M
$5M
$528K
$983K
$983K
$983K
$655K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$5M
$5M
$528K
$983K
$983K
$983K
$655K
Selling, general and administrative
$6.81M
$6.89M
$6.13M
$4.18M
$4.09M
$3.96M
$3.98M
$3.9M
Research and development
$10.84M
$8.48M
$9.33M
$8.99M
$7.77M
$6.04M
$6.56M
$5.35M
Total operating expenses
$17.64M
$15.37M
$15.46M
$13.17M
$11.87M
$10M
$10.53M
$9.25M
Operating income
-$17.64M
-$10.37M
-$10.46M
-$12.64M
-$10.89M
-$9.02M
-$9.55M
-$8.59M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$129.72M
$50.18M
-$127.51M
-$183.16M
-$71.64M
$39.75M
-$26.97M
-$28.04M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$129.72M
$50.18M
-$127.51M
-$183.16M
-$71.64M
$39.75M
-$26.97M
-$28.04M
Net income attributable to common shareholders
-$129.72M
$32.04M
-$127.51M
-$183.16M
-$71.64M
$21.81M
-$26.97M
-$28.04M
EBITDA
-$17.59M
-$10.32M
-$10.39M
-$12.59M
-$10.82M
-$8.88M
-$9.26M
-$8.27M
Basic earnings per share
-$11.02
$2.75
-$11.65
-$19.97
-$8.36
$2.55
-$7.43
-$8.60
Diluted earnings per share
-$11.02
-$0.41
-$11.65
-$19.97
-$8.36
$2.55
-$7.43
-$8.60
Recent news
Company coverage with links to the original publishers.
Surrozen, Inc. (Nasdaq: SRZN), a biotechnology company focused on Wnt-based therapeutics for ophthalmic conditions, announced that management will present at Guggenheim's 3rd Annual Healthcare Innovation Conference on November 10, 2026. The company is developing targeted treatments for sight-threatening eye diseases, with plans to dose the first patient in the DUET Phase 1b/2a study for diabetic macular edema in Q4 2026 and expects initial data in H2 2027.
Surrozen, Inc. (NASDAQ: SRZN) announced the closing of its second tranche of a private placement, raising approximately $95.1 million in gross proceeds. The closing was triggered by FDA clearance of the IND application for SZN-8141 on October 2, 2026. The company now has cash runway into 2029 to advance its ophthalmology pipeline, including the DUET Phase 1b/2a study of SZN-8141 for diabetic macular edema and initial clinical development of SZN-8143. First patient dosing in the DUET study is expected in Q4 2026, with initial data anticipated in H2 2027.
Biotechnology company Surrozen reported a surprising Q2 2025 net income of $39.7 million, driven primarily by non-cash gains, while continuing to advance its ophthalmology pipeline focused on Wnt pathway modulation.